Trial Profile
A Comparative Single-Dose Pharmacokinetic and Safety Study of TAK-491 Between Infants, Children, and Adolescents With Hypertension and Healthy Adults
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 24 Sep 2019
Price :
$35
*
At a glance
- Drugs Azilsartan medoxomil (Primary)
- Indications Hypertension
- Focus Pharmacokinetics
- Sponsors Takeda; Takeda Development Centre Europe; Takeda Global Research and Development Center
- 04 Jan 2016 Results published in the European Journal of Clinical Pharmacology
- 09 Oct 2013 Status changed from recruiting to discontinued as reported by CliniclTrials.gov.
- 28 Jan 2013 Planned End Date changed from 1 May 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.